K. Erturk Et Al. , "Clinical significance of serum interleukin-29, interleukin-32, and tumor necrosis factor alpha levels in patients with gastric cancer," TUMOR BIOLOGY , vol.37, no.1, pp.405-412, 2016
Erturk, K. Et Al. 2016. Clinical significance of serum interleukin-29, interleukin-32, and tumor necrosis factor alpha levels in patients with gastric cancer. TUMOR BIOLOGY , vol.37, no.1 , 405-412.
Erturk, K., Tastekin, D., Serilmez, M., Bilgin, E., Bozbey, H. U., & Vatansever, S., (2016). Clinical significance of serum interleukin-29, interleukin-32, and tumor necrosis factor alpha levels in patients with gastric cancer. TUMOR BIOLOGY , vol.37, no.1, 405-412.
Erturk, Kayhan Et Al. "Clinical significance of serum interleukin-29, interleukin-32, and tumor necrosis factor alpha levels in patients with gastric cancer," TUMOR BIOLOGY , vol.37, no.1, 405-412, 2016
Erturk, Kayhan Et Al. "Clinical significance of serum interleukin-29, interleukin-32, and tumor necrosis factor alpha levels in patients with gastric cancer." TUMOR BIOLOGY , vol.37, no.1, pp.405-412, 2016
Erturk, K. Et Al. (2016) . "Clinical significance of serum interleukin-29, interleukin-32, and tumor necrosis factor alpha levels in patients with gastric cancer." TUMOR BIOLOGY , vol.37, no.1, pp.405-412.
@article{article, author={Kayhan ERTÜRK Et Al. }, title={Clinical significance of serum interleukin-29, interleukin-32, and tumor necrosis factor alpha levels in patients with gastric cancer}, journal={TUMOR BIOLOGY}, year=2016, pages={405-412} }